Madrigal’s Rezdiffra Drives Blockbuster Growth Amid Costs

Madrigal ((MDGL)) has held its Q1 earnings call. Read on for the main highlights of the call.

Madrigal’s latest earnings call struck a confident tone as management highlighted blockbuster momentum for Rezdiffra alongside an expanding pipeline and market. Executives balanced that optimism with candor about heavier spending, gross‑to‑net headwinds, and the reality that profitability remains a few years away, framing today’s investments as the price of securing a durable long‑term franchise.

Blockbuster Revenues Mark a Breakout Quarter

Rezdiffra has firmly crossed into blockbuster territory, with trailing 12‑month net sales topping $1.1 billion. First‑quarter 2026 net sales reached $311.3 million, up 127% year over year, underscoring rapid adoption and supporting the company’s view that its lead asset is still early in its commercial ramp.

Patient Growth and Addressable Market Expansion

Active Rezdiffra patients climbed past 42,250 by quarter end, roughly 2.5 times the level a year earlier, signaling strong underlying demand. The U.S. diagnosed F2/F3 population, Madrigal’s core market, has expanded from about 315,000 at the end of 2023 to roughly 460,000 by 2025, nearly a 50% increase that broadens the long‑term revenue opportunity.

Pipeline Expansion with siRNA and Multiple Programs

Madrigal now counts more than 10 programs in its pipeline, highlighted by the in‑licensed ARO‑PNPLA3, a clinical‑stage siRNA asset. In Phase I testing, ARO‑PNPLA3 delivered up to a 46% reduction in liver fat at 12 weeks after a single dose in PNPLA3 homozygous patients, a genetically defined subgroup that represents roughly 30% of F2–F3 patients.

Advancing Outcomes Trials with Defined Timelines

The company is running an event‑driven F4C outcomes trial for Rezdiffra, with a readout expected in 2027 that could help solidify long‑term positioning in advanced disease. A separate histology‑driven Phase III in F2/F3 patients is slated to produce data in 2028, and open‑label results showing 65% of CSPH patients moving to lower‑risk categories by year two lend early support to the F4C strategy.

Broad Commercial Execution and Real‑World Evidence

More than 10,000 prescribers have now written Rezdiffra, supported by first‑line payer access and growing real‑world data across liver stiffness, MRI‑PDFF, enzymes, LDL‑C and Lp(a). The company cited its best MBRx week last quarter and its best NBRx month since launch in April, while over 40 abstracts at scientific meetings are helping to translate clinical evidence into broader adoption.

Financial Resources Underpin Growth Strategy

Madrigal ended the quarter with $817.9 million in cash, cash equivalents, restricted cash and marketable securities, a war chest it says is sufficient to fund launch and pipeline plans. Management emphasized that this capital base also supports ongoing business development, positioning the company to continue adding assets like ARO‑PNPLA3 without jeopardizing core operations.

Net Loss Highlights Near‑Term Profit Pressure

The company reported a first‑quarter 2026 net loss of $94.4 million, up from $73.2 million a year earlier, reflecting both growth investments and one‑time charges. A $54.3 million upfront business development expense weighed on the quarter, and management was clear that 2026, including the second quarter, will remain unprofitable as strategic spending continues.

Operating Expenses Surge on R&D and SG&A

Research and development costs jumped to $108.7 million from $44.2 million, a roughly 146% increase driven largely by upfront business development outlays. SG&A rose to $268.5 million from $167.9 million, about a 60% gain, as Madrigal expands its endocrinology field force, invests in direct‑to‑consumer efforts, and steps up marketing to capture share.

Higher Cost of Sales and Royalty Drag

Cost of sales surged to $26.8 million from $4.5 million year over year, a nearly five‑fold increase tied mainly to royalties owed to Roche. This growing royalty burden is pressuring gross margins even as volumes rise, introducing another layer of complexity for investors focused on the eventual earnings power of Rezdiffra.

Gross‑to‑Net Discounts Trim Realized Revenue

Management now expects gross‑to‑net discounts to run in the mid‑ to high‑30% range for the rest of 2026, which will meaningfully reduce net revenue compared with headline gross sales. The company framed these discounts as the cost of broad payer access, but they temper near‑term margin expansion even as top‑line demand remains robust.

Strategic Capital Deployment Reduces Cash Levels

Cash and equivalents declined to $817.9 million from $988.6 million at the end of 2025, a roughly 17% drop largely tied to business development payments and active pharmaceutical ingredient purchases. Management portrayed these outlays as deliberate investments to fortify the pipeline and build inventory, trading short‑term balance‑sheet strength for future growth.

Early‑Stage Market with Long Runway

Despite the larger diagnosed pool, Madrigal estimates the diagnosis rate is just over 10%, and Rezdiffra penetration is still just under 10% of the 460,000 eligible patients, underscoring how early the market is. This low penetration represents a sizable long‑run upside but also a near‑term execution challenge, as the company must drive both disease recognition and therapy adoption.

Multi‑Year Clinical and Execution Risks

Key clinical readouts are years away, with F4C outcomes data expected in 2027 and F2/F3 histology data not slated until 2028, leaving investors exposed to trial‑execution and event‑rate risks. The success or failure of these studies will heavily influence indication expansion and peak revenue, reinforcing the high‑stakes nature of Madrigal’s current development cycle.

Guidance Emphasizes Growth and Inevitable Profitability

Madrigal reiterated its 2026 growth and financial guidance, pointing to Q1 net sales of $311.3 million and more than 42,250 active patients as a strong starting point for steady patient additions through the year. The company expects gross‑to‑net discounts in the mid‑ to high‑30% range, R&D spending roughly flat versus 2025, higher SG&A with a second‑quarter spike, and a recorded upfront payment for ARO‑PNPLA3, and while management does not foresee profitability in 2026, they described eventual profitability as inevitable once current investments begin to pay off.

Madrigal’s earnings call painted a picture of a company trading short‑term margins and cash for long‑term value in a still‑nascent market. For investors, the story combines blockbuster‑level revenue growth, expanding scientific ambition, and sizable clinical and financial execution risks, making future trial readouts and commercial performance the key drivers of the stock’s trajectory.